Search results for " Control"

showing 10 items of 7691 documents

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Oligo-antigenic diet in the treatment of chronic anal fissures. Evidence for a relationship between food hypersensitivity and anal fissures.

2013

Abstract OBJECTIVES: Patients with chronic constipation due to food hypersensitivity (FH) had an elevated anal sphincter resting pressure. No studies have investigated a possible role of FH in anal fissures (AFs). We aimed to evaluate (1) the effectiveness of diet in curing AFs and to evaluate (2) the clinical effects of a double-blind placebo-controlled (DBPC) challenge, using cow's milk protein or wheat. METHODS: One hundred and sixty-one patients with AFs were randomized to receive a "true-elimination diet" or a "sham-elimination diet" for 8 weeks; both groups also received topical nifedipine and lidocaine. Sixty patients who were cured with the "true-elimination diet" underwent DBPC cha…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaConstipationManometryTreatment outcomeFood habitsSettore MED/08 - Anatomia PatologicaGastroenterologyFissure in anolaw.inventionLeukocyte CountFeeding behaviorRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicinemedicineHumansLymphocyte CountLymphocytesIntestinal MucosaTriticumHepatologybusiness.industryGastroenterologyFeeding BehaviorMiddle AgedMilk ProteinsSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheFood hypersensitivitySurgeryEosinophilsSettore MED/18 - Chirurgia GeneraleChronic diseaseTreatment OutcomeChronic DiseasefissureFemaleFissure in Anohypersensitivitymedicine.symptomMilk HypersensitivitybusinessConstipationFood HypersensitivityThe American journal of gastroenterology
researchProduct

Percutaneous liver biopsy: a safe outpatient procedure?

2001

Following the discovery of hepatitis C virus, more liver biopsies (LB) than before are being performed to assess the severity of liver disease. In this study, following the recommendations for outpatient LB made by the Patient Care Committee of the American Gastroenterological Association, we assessed the feasibility and benefits of LB performed as an outpatient versus inpatient procedure over the last 7 years in our centre. The study included 1,581 patients consecutively examined in our institute; all LBs were performed by a single operator with a 16-gauge needle using the Menghini technique, and in all cases the puncture site was determined using prebiopsy ultrasound. Liver lesions were c…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCost ControlChronic liver diseaseLiver biopsy complicationLiver diseasePatient satisfactionAmbulatory careBiopsyAmbulatory CareMedicineHumansAgedRetrospective StudiesUltrasonographymedicine.diagnostic_testbusiness.industryPatient SelectionChronic liver diseaseBiopsy NeedleHaemobiliaGastroenterologyOutpatientRetrospective cohort studyHealth Care CostsMiddle Agedmedicine.diseaseSurgeryLiverPatient SatisfactionFemalebusinessComplicationDigestion
researchProduct

Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A …

2006

BACKGROUND: Desquamative gingivitis (DG) is a clinical condition characterized by red, painful, glazed, and friable gingiva, which might be a manifestation of some autoimmune mucocutaneous diseases. The time from the development of initial signs of DG to diagnosis can vary from months to years. Based on a literature search, no data concerning patients with DG without signs of autoimmune disease were available. OBJECTIVE: The aim of this trial was to compare the efficacy and tolerability of monotherapy with topical tacrolimus 0.1% in pectin ointment versus clobetasol propionate 0.5% ointment in adults affected by DG. METHODS: This randomized, double-blind clinical trial was conducted at the …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaErythemaAdministration TopicalPopulationSeverity of Illness IndexTacrolimuslaw.inventionOintmentsRandomized controlled trialDouble-Blind Methodlawdesquamative gingivitimedicineClinical endpointHumansPharmacology (medical)educationAgedPharmacologyeducation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseDermatologyGingivitisdesquamative gingivitisTacrolimusSurgeryDesquamative gingivitisTreatment OutcomeTolerabilityclobetasoltopical tacrolimus; clobetasol; desquamative gingivitis; randomized double-blind clinical trialtacrolimus clobetasol desquamative gingivitisPectinsDrug Therapy CombinationFemaleClobetasol propionatemedicine.symptombusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studiestopical tacrolimurandomized double-blind clinical trial
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus.

2008

Background Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology that affects the mucosae, especially the oral cavity. Objective We compared tacrolimus 0.1% ointment and clobetasol 0.05% ointment for the treatment of OLP. Patients and methods A total of 32 patients (20 females and 12 males; all white, Italian origin, mean age of 43.6+/-18.4 years; 16 patients per treatment group) were treated with tacrolimus or clobetasol ointment for 4 weeks in a randomized, double-blind, clinical trial. Pain severity, burning sensation, and mucosal lesion extension were assessed using a four-point scale. Results At the end of the treatment period, symptom scores were sign…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_classAnti-Inflammatory Agentstacrolimus ointment; clobetasol ointment; oral lichen planuslaw.inventionOintment Basesoral lichen planusRandomized controlled triallawOral administrationFacial PainmedicineHumanstacrolimus ointmentSalivatacrolimusbusiness.industryclobetasol ointmentclobetasol; tacrolimus; oral lichen planusmedicine.diseaseDermatologyTacrolimusCalcineurinstomatognathic diseasesclobetasolOintment BasesPeriodonticsCorticosteroidOral lichen planusFemaleClobetasol propionatebusinessEpidemiologic MethodsImmunosuppressive Agentsmedicine.drugLichen Planus Oral
researchProduct

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.

2008

Abstract Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical respons…

AdultMalemedicine.medical_specialtySide effectAdolescentmedicine.drug_classPoison controlAtypical antipsychoticSchizoaffective disorderComorbidityGastroenterologyYoung AdultExtrapyramidal symptomsInternal medicinemedicineHumansPharmacology (medical)AmisulpridePsychiatryAgedPharmacologyAged 80 and overDose-Response Relationship DrugDopamine antagonistAge FactorsMiddle Agedmedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridePsychologymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct

Bone Marrow Concentrate and Bovine Bone Mineral for Sinus Floor Augmentation

2011

Purpose: The purpose of this work was to evaluate the potential of substituting autogenous bone (AB) by bone marrow aspirate concentrate (BMAC). Both AB and BMAC were tested in combination with a bovine bone mineral (BBM) for their ability of new bone formation (NBF) in a multicentric, randomized, controlled, clinical and histological noninferiority trial.Materials and Methods: Forty-five severely atrophied maxillary sinus from 26 patients were evaluated in a partial cross-over design. As test arm, 34 sinus of 25 patients were augmented with BBM and BMAC containing mesenchymal stem cells. Eleven control sinus from 11 patients were augmented with a mixture of 70% BBM and 30% AB. Biopsies wer…

AdultMalemedicine.medical_specialtySinus Floor AugmentationOSTEOGENIC DIFFERENTIATIONBone RegenerationMaxillary sinusBiomedical EngineeringSinus Floor AugmentationBioengineeringBiochemistryMAXILLARY SINUSlaw.inventionMESENCHYMAL STEM-CELLSBIO-OSSBiomaterialsRandomized controlled trialTISSUE-ENGINEERED BONEBone MarrowOsteogenesislawmedicineAnimalsHumansSingle-Blind MethodSinus (anatomy)AgedIMPLANT PLACEMENTHYDROXYAPATITE CERAMICSBone TransplantationIntention-to-treat analysisPOROUS HYDROXYAPATITEbusiness.industryIN-VITROMiddle AgedSurgeryAUTOGENOUS BONEImplant placementBovine bonemedicine.anatomical_structureBone SubstitutesCattleFemaleBone marrowbusinessTissue Engineering. Part A
researchProduct

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

2015

The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS).A total of 529 patients were randomized to nab-paclitaxel (n = 264) or dacarbazine (n = 265). Baseline characteristics were well balanced. The majority of patients were men (66%), had an Eastern Cooperative Oncology Group status of 0 (7…

AdultMalemedicine.medical_specialtySkin NeoplasmsPaclitaxelDacarbazineGastroenterologyDisease-Free Survivallaw.inventionYoung AdultRandomized controlled triallawInternal medicineAlbuminsmedicineClinical endpointHumansProgression-free survivalAntineoplastic Agents AlkylatingMelanomaAgedAged 80 and overbusiness.industryMelanomaHazard ratioHematologyOriginal ArticlesMiddle Agedmedicine.diseaseChemotherapy regimenConfidence intervalSurgeryDacarbazineOncologyFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct